ClinicalTrials.gg
Enrolling by invitationNCT05669989Updated Oct 15, 2026

International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab

A Phase 2 interventional study of Isatuximab intravenous (IV) and Cemiplimab (SAR439684) in Plasma Cell Myeloma, sponsored by Sanofi. Enrolling by invitation at 37 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Sanofi · Phase 2, Interventional, and Treatment

Updated Oct 15, 20268 sites added8 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
70
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 50 studies testing isatuximab in Multiple Myeloma — 15 open to participants now, 34 under way, 9 of them phase 3. isatuximab · Multiple Myeloma.

Planned enrollment
20th of 50
70 · median 55
Started
2023
with 8 others
Phase 2
25 of 50
10 open now
Primary completion
2028-11
later than 23 of 33 live
Registered
35th of 50
by date
Lead sponsor
13 of 50
Sanofi

Among the 50 studies testing isatuximab in Multiple Myeloma, this one is the 20th largest by planned enrollment, is one of 9 that started in 2023, is one of 25 in phase 2, reaches primary completion later than 23 of the 33 other live ones, and was the 35th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

15 of the 50 studies testing isatuximab in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About isatuximab

isatuximab: first FDA approval 2020 (SARCLISA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing isatuximab in Multiple Myeloma, or all of them as a file.
02

Study summary

  • This is a multi-center, open-label, Phase 2 treatment extension study in participants with multiple myeloma who are still benefitting from isatuximab based therapy following completion of a Phase 1, 2, or 3 parental study.
  • This Treatment Extension study has the purpose to provide continued access to isatuximab. Adult participants with multiple myeloma who have enrolled on an isatuximab parental study for which study objectives are completed will be eligible to be enrolled in this Treatment Extension study.
  • The primary objective of the study is to assess long-term safety of isatuximab as study treatment.
Read the detailed description

Participants can continue the treatment until disease progression, unacceptable adverse events, participant wish to discontinue study treatment, study treatment is commercially available and reimbursed in participant's country, or for any other reason, whichever comes first. The overall study duration will be of approximately 42 months.

03

Conditions studied

  • Plasma Cell Myeloma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be ≥18 years of age (or the legal age of consent in the jurisdiction in which the study is taking place), at the time of signing the .
  • Participants of a parental Phase 1, 2, or 3 clinical study assessing isatuximab monotherapy or in a combination regimen with all the study objectives completed.
  • Participants still receiving isatuximab at the time of the parental study closure, who are continuing to benefit from isatuximab as monotherapy or in combination, as determined by the treating physician, and who meet the criteria to initiate a subsequent cycle of therapy as described in the parental study protocol. A participant not receiving isatuximab at the end of the parental study who does not have access locally to the ongoing treatment may also be included.
  • (with double contraception methods) for male and female participants; not pregnant or breastfeeding for female participants; no sperm donation for male participants.
  • Capable of giving signed informed consent.

Exclusion criteria

Exclusion Criteria:

  • Participant has evidence of progressive disease during or at the time of the parental study closure.
  • Participant has not recovered to ≤Grade 2 from nonhematologic AEs (as per v5.0) related to any anticancer therapy received prior to signing on the extension study.
  • As the latest participant received an antimyeloma therapy other than the isatuximab-based therapy in the parental study before the first IMP in this study.
  • Individuals accommodated in an institution because of regulatory or legal order; prisoners or participants who are legally institutionalized.
  • Participant not suitable for participation, whatever the reason, as judged by the Investigator, including medical or clinical conditions, or participants potentially at risk of noncompliance to study procedures.
  • Participants are employees of the clinical study site or other individuals directly involved in the conduct of the study, or immediate family members of such individuals.
  • Any country-related specific regulation that would prevent the participant from entering the study.

The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    Isatuximab

    Participants will receive isatuximab as monotherapy or in a combination regimen, according to the treatment the participant received on the parental protocol

    Drug: Isatuximab intravenous (IV) · Drug: Cemiplimab (SAR439684) · Drug: Dexamethasone · Drug: Lenalidomide · Drug: Pomalidomide · Drug: Isatuximab subcutaneous (SC) · Drug: Carfilzomib

Interventions

  • Route of administration: IV infusion; Pharmaceutical form: Vial

    Also known as: SARCLISA®, SAR650984

  • Route of administration: IV infusion; Pharmaceutical form: Vial

  • Route of administration: Oral or IV infusion; Pharmaceutical form: Tablets/single use vial

  • Route of administration: Oral; Pharmaceutical form: Capsules

  • Route of administration: Oral; Pharmaceutical form: Hard capsules

  • Route of administration: SC injection with the investigational isatuximab injector device; Pharmaceutical form: Vial

    Also known as: SARCLISA®, SAR650984

  • Route of administration: IV infusion; Pharmaceutical form: Vial

06

What researchers measure

Primary outcomes

  1. Number of participants with treatment-emergent adverse events

    Time frame: Baseline to 42 months

07

Study locations

37 sites
  • Washington University- Site Number : 8400001
    St Louis, Missouri 63110, United States
  • Investigational Site Number : 0360006
    Blacktown, New South Wales 2148, Australia
  • Investigational Site Number : 0360001
    Saint Leonards, New South Wales 2065, Australia
  • Investigational Site Number : 0360003
    Wollongong, New South Wales 2500, Australia
  • Investigational Site Number : 0360005
    Heidelberg, Victoria 3084, Australia
  • Investigational Site Number : 0360004
    Melbourne, Victoria 3065, Australia
  • Investigational Site Number : 0360002
    Richmond, Victoria 3121, Australia
  • Hospital Mae de Deus- Site Number : 0760003
    Porto Alegre, Rio Grande do Sul 90880-480, Brazil
  • Instituto Americas - Ensino, Pesquisa e Inovação - Rio de Janeiro - Avenida Jorge Curi- Site Number : 0760001
    Rio de Janeiro, 22775-001, Brazil
  • Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo- Site Number : 0760002
    São Paulo, 05403-000, Brazil
  • Investigational Site Number : 1520001
    Temuco, La Araucanía 4780000, Chile
  • Investigational Site Number : 1560001
    Tianjin, 300020, China
  • Investigational Site Number : 2030002
    Brno, 625 00, Czechia
  • Investigational Site Number : 2030003
    Ostrava, 708 52, Czechia
  • Investigational Site Number : 2030001
    Prague, 128 08, Czechia
  • Investigational Site Number : 2460001
    Helsinki, 00029, Finland
  • Investigational Site Number : 2500002
    Nantes, 44093, France
  • Investigational Site Number : 3000004
    Athens, 106 76, Greece
  • Investigational Site Number : 3000003
    Athens, 115 28, Greece
  • Investigational Site Number : 3000001
    Pátrai, 265 04, Greece
  • Investigational Site Number : 3800002
    Turin, Torino 10126, Italy
  • Investigational Site Number : 3920001
    Okayama, Okayama-ken 701-1192, Japan
  • Investigational Site Number : 5540002
    Auckland, 2025, New Zealand
  • Investigational Site Number : 5540001
    Wellington, 6021, New Zealand
  • Investigational Site Number : 6430002
    Kirov, 610027, Russia
  • Investigational Site Number : 6430001
    Moscow, 125284, Russia
  • Investigational Site Number : 4100001
    Seoul, Seoul-teukbyeolsi 03080, South Korea
  • Investigational Site Number : 4100002
    Seoul, Seoul-teukbyeolsi 06591, South Korea
  • Investigational Site Number : 7240006
    Seville, Andalusia 41013, Spain
  • Investigational Site Number : 7240005
    Badalona, Barcelona [Barcelona] 08916, Spain
  • Investigational Site Number : 7240004
    Santander, Cantabria 39008, Spain
  • Investigational Site Number : 7240002
    Salamanca, Castille and León 37007, Spain
  • Investigational Site Number : 7240001
    Pamplona, Navarre 31008, Spain
  • Investigational Site Number : 7241001
    Madrid, 28027, Spain
  • Investigational Site Number : 7240003
    Madrid, 28041, Spain
  • Investigational Site Number : 7520004
    Luleå, 971 80, Sweden
  • Investigational Site Number : 1580001
    Taichung, 404, Taiwan
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for Nov 2028, 67 months after the start.

Of 93 industry-sponsored phase 2 interventional studies under Multiple Myeloma, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 77. This study's planned 67 months is above that.

Counting every sponsor, half of 506 studies reached it within 57 months; a quarter within 35 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 20, 2022
First posted
Jan 3, 2023
StartActual
Apr 5, 2023
Primary completionEst.
Nov 30, 2028
CompletionEst.
Nov 30, 2028
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
8 sites added, 8 sites removed
Show 8 added (3 Spain, 1 Australia, 1 Brazil, 1 Chile, 1 Italy, 1 Japan)
  • Investigational Site Number : 0360005 · Heidelberg, Australia
  • Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo- Site Number : 0760002 · São Paulo, Brazil
  • Investigational Site Number : 1520001 · Temuco, Chile
  • Investigational Site Number : 3800002 · Turin, Italy
  • Investigational Site Number : 3920001 · Okayama, Japan
  • Investigational Site Number : 7240005 · Badalona, Spain
  • Investigational Site Number : 7240002 · Salamanca, Spain
  • Investigational Site Number : 7241001 · Madrid, Spain
Show 8 removed
  • Investigational Site Number : 0360005 · Melbourne, Australia
  • Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo - HCFMUSP- Site Number : 0760002 · São Paulo, Brazil
  • Investigational Site Number : 1520001 · Temuco, Chile
  • Investigational Site Number : 3800002 · Torino, Italy
  • Investigational Site Number : 3920001 · Okayama, Japan
  • Investigational Site Number : 7240005 · Badalona, Spain
  • Investigational Site Number : 7241001 · Madrid, Spain
  • Investigational Site Number : 7240002 · Salamanca, Spain
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    8 sites added, 8 sites removed
    Show 8 added (3 Spain, 1 Australia, 1 Brazil, 1 Chile, 1 Italy, 1 Japan)
    • Investigational Site Number : 0360005 · Heidelberg, Australia
    • Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo- Site Number : 0760002 · São Paulo, Brazil
    • Investigational Site Number : 1520001 · Temuco, Chile
    • Investigational Site Number : 3800002 · Turin, Italy
    • Investigational Site Number : 3920001 · Okayama, Japan
    • Investigational Site Number : 7240005 · Badalona, Spain
    • Investigational Site Number : 7240002 · Salamanca, Spain
    • Investigational Site Number : 7241001 · Madrid, Spain
    Show 8 removed
    • Investigational Site Number : 0360005 · Melbourne, Australia
    • Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo - HCFMUSP- Site Number : 0760002 · São Paulo, Brazil
    • Investigational Site Number : 1520001 · Temuco, Chile
    • Investigational Site Number : 3800002 · Torino, Italy
    • Investigational Site Number : 3920001 · Okayama, Japan
    • Investigational Site Number : 7240005 · Badalona, Spain
    • Investigational Site Number : 7241001 · Madrid, Spain
    • Investigational Site Number : 7240002 · Salamanca, Spain
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05669989
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Jan 3, 2023
Start date
Apr 5, 2023
Primary completion
Nov 30, 2028 (estimated)
Completion
Nov 30, 2028 (estimated)
Last update
Oct 15, 2026

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Isatuximab

Start the discussion